Arcutis Q2 Shows $129.9 Million in ZORYVE Sales, but the Stock Still Needs a Cleaner Buy Signal

ZORYVE sales, guidance, and profitability all improved in one quarter

Arcutis delivered a clean, easy-to-read second quarter. ZORYVE Q2 revenue of $129.9 million grew 59% versus last year and 23% versus Q1, and management paired that with a higher 2026 full-year outlook of $525 million to $540 million. Arcutis also posted $15 million in net income and generated $12.6 million in operating cash flow. For investors, that is a straightforward scorecard: stronger sales, higher guidance, and enough cash generation to support the business without relying on obvious financial engineering.

The main debate is not whether the quarter looked good. It is whether the stock has already run ahead of the next set of confirmations. By itself, the operating performance still looks credible.

ZORYVE demand looks real, but economics and execution still need proof

Prescription growth and label expansions support the commercial story

ZORYVE generated more than 280,000 prescriptions in the quarter, which is a practical signal that prescribing and patient uptake remain healthy. That matters alongside FDA approval in children as young as 2 for plaque psoriasis. Age expansions can widen the treatable population and make a therapy easier to recommend early in the treatment conversation.

There is another potential expansion on the way. The FDA accepted the supplemental NDA for infants with atopic dermatitis and set a target action date of February 23, 2027. That does not guarantee approval, but it does mean the submission advanced.

Arcutis also launched a virtual health platform and an AI-enabled prescription workflow partnership to simplify access. Those moves are small but relevant because they target friction points between the doctor visit and the patient fill.

Gross-to-net remains the main dampener on upside

The clearest watchpoint is economics. Management has indicated gross-to-net rates remain in the 50s and pointed to only modest improvement in the second half, with the mix trending toward the low 50s. If that holds, a meaningful share of sales growth could be offset before results reach the company.

That is why a strong prescription story does not automatically translate into a strong investment case. Investors still need evidence that the revenue growth is becoming more profitable, not just bigger.

The full commercial build may not fully show up until 2027

Arcutis has also warned that the primary care and pediatric sales team is expected to drive growth in 2027 rather than this year. That leaves a gap between what the market may be anticipating and what the current quarter actually captures.

Leadership turnover adds another execution variable. Chief Commercial Officer Todd Edwards is departing, with Rob Lisicky serving as interim chief commercial officer during the search.

What could turn a solid quarter into a cleaner buy signal

The near-term catalyst path is reasonably clear.

Vitiligo results come first

First comes Q4 2026 vitiligo Phase 2 results and advancement decision. This is the first meaningful test of whether ZORYVE can extend beyond Arcutis's current indications, even if a positive readout would not by itself resolve reimbursement or gross-to-net concerns.

Infant atopic dermatitis approval would widen the commercial opportunity

Second comes the February 23, 2027 PDUFA for the infant atopic dermatitis indication. Approval would likely expand the commercial opportunity, but it would still need to fit within the same gross-to-net and payers-and-access framework that is already shaping ZORYVE economics.

The market has already shown some tolerance for operating noise

Arcutis has not needed a perfect quarterly print to keep investor attention. In the first quarter, it reported a $0.09 per-share miss, yet shares still rose 2.7% in the session. That does not guarantee the same reaction next time, but it does show the market has been willing to look past a modest earnings miss when the operating story looked intact.

For now, the stock still looks more like a commercial story in motion than a fully confirmed trend. The quarter strengthened that view, but investors still need the next catalysts to line up before the buy signal looks cleaner.